Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease.
Roskrow
M A
MA
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA.
Rooney
C M
CM
Heslop
H E
HE
Brenner
M K
MK
Krance
R A
RA
Gresik
M V
MV
McClain
K
K
Aguilar
L K
LK
Grilley
B
B
Rob
E
E
Carrum
G
G
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002460:Cell Line; D004352:Drug Resistance, Microbial / Q000235:genetics; D005240:Feasibility Studies; D005814:Genes, Viral; D005819:Genetic Markers; D005822:Genetic Vectors; D004854:Herpesvirus 4, Human / Q000235:genetics*; D006689:Hodgkin Disease / Q000821:virology*; D006801:Humans; D007275:Injections, Intravenous; D009355:Neomycin / Q000494:pharmacology*; D009364:Neoplasm Recurrence, Local; D012190:Retroviridae / Q000235:genetics; D013602:T-Lymphocytes, Cytotoxic
D000900:Anti-Bacterial Agents; D005819:Genetic Markers; D009355:Neomycin